Therapeutic Results Of Our Acromegalic Patients

Volume: 29 Number: 3 September 1, 2003
  • Erdinç Ertürk
  • Ercan Tuncel
  • Sinem Kıyıcı
  • Canan Ersoy
  • Cevdet Duran
  • Şazi İmamoğlu
EN TR

Therapeutic Results Of Our Acromegalic Patients

Abstract

We aimed to evaluate our therapy results in acromegalic patients for last ten years. Although 52 acromegalic patients admitted to our center, only 30 (M/F: 13/17) patients whose follow-up data were available enrolled into the study. Their mean age was 43 ± 38 (28-64) years, mean age of diagnosis was 39 ± 9 (26-60) years and mean follow-up period was 42 ± 38 (5-127) months. Basal or nadir postglucose GH level less than 2 ng/ml accepted as cure criteria. After diagnosis, all patients operated transsphenoidally in different medical centers by different surgeons and the cure rate of first operation was 33 % (10/30). The cure rates were 63 % and 15 % in patients with microadenomas (n=11) and macroadenomas (n=19) respectively. And the difference was statistically significant (pIn conclusion cure rate probability was found higher in patients with microadenomas after transsphenoidal operation while it was very low in patients with macroadenomas. Our low cure rates could be attributed to the fact that the operations have been performed by inexperienced surgeons. While cure probability decreases after the second operation, complication risk increases. Octreotide therapy, which could be used as an alternative choice to the surgery, revealed high success rates in microadenomas and macroadenomas.

Keywords

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Erdinç Ertürk This is me

Ercan Tuncel This is me

Sinem Kıyıcı This is me

Canan Ersoy This is me

Cevdet Duran This is me

Şazi İmamoğlu This is me

Publication Date

September 1, 2003

Submission Date

September 1, 2003

Acceptance Date

-

Published in Issue

Year 2003 Volume: 29 Number: 3

APA
Ertürk, E., Tuncel, E., Kıyıcı, S., Ersoy, C., Duran, C., & İmamoğlu, Ş. (2003). Therapeutic Results Of Our Acromegalic Patients. Journal of Uludağ University Medical Faculty, 29(3), 39-45. https://izlik.org/JA48FD45XX
AMA
1.Ertürk E, Tuncel E, Kıyıcı S, Ersoy C, Duran C, İmamoğlu Ş. Therapeutic Results Of Our Acromegalic Patients. Journal of Uludağ University Medical Faculty. 2003;29(3):39-45. https://izlik.org/JA48FD45XX
Chicago
Ertürk, Erdinç, Ercan Tuncel, Sinem Kıyıcı, Canan Ersoy, Cevdet Duran, and Şazi İmamoğlu. 2003. “Therapeutic Results Of Our Acromegalic Patients”. Journal of Uludağ University Medical Faculty 29 (3): 39-45. https://izlik.org/JA48FD45XX.
EndNote
Ertürk E, Tuncel E, Kıyıcı S, Ersoy C, Duran C, İmamoğlu Ş (September 1, 2003) Therapeutic Results Of Our Acromegalic Patients. Journal of Uludağ University Medical Faculty 29 3 39–45.
IEEE
[1]E. Ertürk, E. Tuncel, S. Kıyıcı, C. Ersoy, C. Duran, and Ş. İmamoğlu, “Therapeutic Results Of Our Acromegalic Patients”, Journal of Uludağ University Medical Faculty, vol. 29, no. 3, pp. 39–45, Sept. 2003, [Online]. Available: https://izlik.org/JA48FD45XX
ISNAD
Ertürk, Erdinç - Tuncel, Ercan - Kıyıcı, Sinem - Ersoy, Canan - Duran, Cevdet - İmamoğlu, Şazi. “Therapeutic Results Of Our Acromegalic Patients”. Journal of Uludağ University Medical Faculty 29/3 (September 1, 2003): 39-45. https://izlik.org/JA48FD45XX.
JAMA
1.Ertürk E, Tuncel E, Kıyıcı S, Ersoy C, Duran C, İmamoğlu Ş. Therapeutic Results Of Our Acromegalic Patients. Journal of Uludağ University Medical Faculty. 2003;29:39–45.
MLA
Ertürk, Erdinç, et al. “Therapeutic Results Of Our Acromegalic Patients”. Journal of Uludağ University Medical Faculty, vol. 29, no. 3, Sept. 2003, pp. 39-45, https://izlik.org/JA48FD45XX.
Vancouver
1.Erdinç Ertürk, Ercan Tuncel, Sinem Kıyıcı, Canan Ersoy, Cevdet Duran, Şazi İmamoğlu. Therapeutic Results Of Our Acromegalic Patients. Journal of Uludağ University Medical Faculty [Internet]. 2003 Sep. 1;29(3):39-45. Available from: https://izlik.org/JA48FD45XX

ISSN: 1300-414X, e-ISSN: 2645-9027

Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023